that this is indeed not only an extremely valuable technique, but also safe for post-breast cancer patients. It is, to our knowledge, the largest observational study to date on one of the most important questions in our field. It will have a significant impact on the plastic surgery community and will be largely discussed by our colleagues.
However, some issues with the reporting of the findings limit the extent to which readers can understand the findings and may ultimately jeopardize the conclusions. The most relevant measure of disease occurrence reported in the Results section are the average incidence rate (0.25 case per 100 person-years in cases versus 0.65 case per 100 person-years in controls) and cumulative recurrence risk (1.6 percent versus 4.1 percent at 5 years). These results show a risk of recurrence approximately 2.5 times higher in the control group and, if directly compared, could suggest that lipofilling might be protective for locoregional recurrence. Even if not statistically significant, this is not a negligible difference. However, recurrence-free survival time was defined as the interval from the date of mastectomy to the date of first locoregional recurrence or the date of last follow-up, biasing the estimated risk in the lipofilled group, a form of bias in survival analysis known as immortal time bias, 2 as subjects at a higher risk of recurrence after mastectomy probably had a lower chance of receiving a posterior lipofilling procedure. This could single-handedly explain the observed difference between the groups. As stated in the article, one of the possible approaches to this issue is the use of the time-dependent Cox proportional hazard regression model. However, in Table 3 , where the results for this analysis are presented, the hazard ratios and their confidence interval are omitted, and the conclusions are based solely on the calculated p values. Assuming that a value of p > 0.05 means that there is no difference between groups is a common misconception of the meaning of the p value (p value fallacy). 3 Adequate reporting of the results of the statistical model should include the measures of disease association and their confidence interval, allowing readers to adequately evaluate the difference in risk observed between the groups. 
Sir:
We appreciate the comments and the refinements to the upper pole placement of the acellular dermal matrix using the bioengineered breast. Minimizing contamination within the implant pocket by using techniques that will achieve this is always welcome.
The principle of bioengineered breasts includes using cells, regenerative matrices, and highly cohesive gel implants. These principles are used both in a prepectoral and a dual-plane position in reconstructive surgery. This principle also extends to aesthetic revision procedures when similar reinforcements and additions are needed to create an aesthetically pleasing form. Upper pole acellular dermal matrix is sometimes placed posterior to the pectoralis major and sometimes anterior to it. In either case in which the upper pole acellular dermal matrix is being placed, we appreciate the comments by Drs. Zhang and Blanchet with their suggested refinement to this technique.
